Subscribe To
ILMN / Illumina cuts annual profit forecast
ILMN News
By Zacks Investment Research
October 26, 2023
LGND vs. ILMN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina ( more_horizontal
By Zacks Investment Research
October 20, 2023
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately. more_horizontal
By Reuters
October 17, 2023
Activist Icahn sues Illumina board over Grail acquisition - FT
Activist-investor Carl Icahn said his firm had sued current and former board directors at Illumina concerning the acquisition of gene-sequencing compa more_horizontal
By Market Watch
October 13, 2023
Illumina responds to EC Grail divestiture order
Illumina Inc. ILMN, -1.10% responded Friday to an order it received Thursday from the European Commission directing the company to divest its $7.1 bil more_horizontal
By Reuters
October 13, 2023
Illumina to divest cancer test maker Grail if it does not win challenge in EU court
Illumina said on Friday it would divest cancer test maker Grail in 12 months, according to the terms of the order by the European Commission, if it do more_horizontal
By Proactive Investors
October 12, 2023
Illumina ordered by European Commission to sell cancer test maker Grail
Illumina Inc (NASDAQ:ILMN), a genetic testing company, has been ordered by EU antitrust regulators to sell Grail after closing its takeover of the can more_horizontal
By Reuters
October 12, 2023
Illumina ordered by EU antitrust regulators to sell Grail
U.S. genetic testing company Illumina has been ordered by EU antitrust regulators to sell cancer test maker Grail after it completed the deal before s more_horizontal
By Reuters
October 11, 2023
Illumina to divest Grail if it loses final court appeals
Illumina Inc said on Wednesday it will divest Grail if the company loses the final appeals in U.S. or European courts. more_horizontal